Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial.

Journal:
Diabetes Care
Published:
DOI:
10.2337/dc25-1080
Affiliations:
23
Authors:
491
Institutions Authors Share
Novo Nordisk, Denmark
5.000000
0.23
Changhua Christian Hospital, Taiwan
1.000000
0.05
Imperial College London (ICL), United Kingdom (UK)
1.000000
0.05
Universidad Autónoma de Guadalajara (UAG), Mexico
1.000000
0.05
The University of North Carolina at Chapel Hill (UNC), United States of America (USA)
1.000000
0.05
Dalhousie University, Canada
1.000000
0.05
University Hospital Aachen (UKA), RWTH Aachen, Germany
1.000000
0.05
University of Nebraska Medical Center (UNMC), United States of America (USA)
1.000000
0.05
University of KwaZulu-Natal (UKZN), South Africa
1.000000
0.05
Yale University, United States of America (USA)
1.000000
0.05
National Academy of Medical Sciences of Ukraine (NAMS), Ukraine
1.000000
0.05
University of Washington (UW), United States of America (USA)
1.000000
0.05
Oregon Health and Science University (OHSU), United States of America (USA)
1.000000
0.05
Hospital Universitario Fundación Alcorcón, Spain
1.000000
0.05
UCL, United Kingdom (UK)
1.000000
0.05
The University of Texas Southwestern Medical Center (UT Southwestern Medical Center), United States of America (USA)
0.500000
0.02
Parkland Health and Hospital System, United States of America (USA)
0.500000
0.02
University of Erlangen-Nuremberg (FAU), Germany
0.500000
0.02
KfH-Nierenzentrum, Germany
0.500000
0.02
German Center for Diabetes Research (DZD), Germany
0.333333
0.02
Helmholtz Zentrum München - German Research Center for Environmental Health (HMGU), Germany
0.333333
0.02
University Hospital Tübingen (UKT), Uni Tübingen, Germany
0.333333
0.02